Navigation Links
Researchers identify new pathway, enhancing tamoxifen to tame aggressive breast cancer
Date:4/23/2013

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.

The research, published in the journal EMBO Molecular Medicine, is a promising development for women with basal-like breast cancer, sometimes known as triple-negative disease. This subtype has a poor prognosis because it is notoriously resistant to treatment. In fact, basal-like cancers lack the three most common breast cancer biomarkers the estrogen receptor, the progesterone receptor, and theHer2/neu receptor and without these receptors, the usual front-line treatments are not effective.

Until recently, tamoxifen was known primarily for its ability to block estrogen receptors on the outside of cancer cells. However, new studies have suggested that when tamoxifen is given in higher doses, it works through a second mechanism of action independent of the estrogen receptor. This second mechanism was the focus of the Rochester laboratory.

Led by doctoral student Hsing-Yu Chen and Mark Noble, Ph.D., professor of Biomedical Genetics at URMC, the team studied the molecular mechanism that allows basal-like breast cancer cells to escape the secondary effects of tamoxifen, and discovered that two proteins are critical in this escape. One protein, called c-Cbl, controls the levels of multiple receptors that are critical for cancer cell function. A second protein, Cdc42, can inhibit c-Cbl and is responsible for the tumor's underlying resistance.

The team also discovered that targeting Cdc42 and thus inhibiting the inhibitor - with an experimental drug compound known as ML141 restored c-Cbl's normal function. Through additional work in animal models and in human cell cultures, the team demonstrated that when ML141 is paired with tamoxifen, it enhances the ability of tamoxifen to induce cancer cell death and suppress the growth of new cancer cells. Neither drug alone had the same effect on basal-like breast cells.

Noble believes there is considerable value to targeting Cdc42, because elevated levels of the protein have been observed in multiple types of cancer. (In this context, scientists are also studying the potential for tamoxifen as a therapy for other cancers.)

The powerful ML141-tamoxifen drug combination looks like it has two more important features: It selectively targets cancer cells while sparing normal, healthy cells; and it appears to cripple cancer stem cells, the primitive cells responsible for initiating new tumors and for fueling the bulk of the tumor cell population.

"Our work is very exciting because our approach simultaneously addresses two of the most critical challenges in cancer research -- to increase the utility of existing therapies and to discover new vulnerabilities of cancer cells," said Noble, who also is a leader at UR's Stem Cell and Regenerative Medicine Institute. "Based on these discoveries, we are already pushing forward with new compounds and with new approaches that might make clinical translation of this discovery much more rapid than would occur with traditional drug-discovery approaches."


'/>"/>

Contact: Leslie Orr
leslie_orr@urmc.rochester.edu
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Researchers develop a new cell and animal model of inflammatory breast cancer
3. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
4. Researchers Find Gene Mutations That May Be a Key to Autism
5. Researchers find evidence of banned antibiotics in poultry products
6. NJ stroke researchers report advances in spatial neglect research at AAN Conference
7. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
8. Researchers Map Brain Regions Linked to Intelligence
9. Researchers ID Genes That May Determine Mental Illness
10. Researchers Develop Blood Test for Depression
11. University of Cincinnati researchers win $3.7M grant from US Department of Defense
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania ... domain address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found ... along with its redesigned and retooled website. The treatment center has also revamped ...
(Date:1/23/2017)... ... 2017 , ... Ultimate Medical Academy today announced the keynote ... March 23-25, 2017 in Tampa, and reminded educators and education leaders to submit ... Dr. Michelle R. Weise, executive director of the Sandbox Collaborative, the R&D arm ...
(Date:1/23/2017)... ... ... and plastic balance boards have been around since at least the 1950s and are a ... first and only balance board to use a patent-pending design featuring high-pressure inflation technology and ... as well as skill-level adjustable for all ages and abilities. The board can be ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the premiere organization in North America for the scientific development, healthcare training and ... Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses for Technicians, ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... However, choosing the right method is paramount to success. Selecting an inappropriate measurement ... situations where multiple persons use the same equipment. Rare or expensive substances are ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... New York , January 23, 2017 ... Non-Invasive Prenatal Testing Market was valued at US$0.53 bn in ... expanding at a strong 17.50% CAGR between 2014 and 2022. The ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... Non-invasive ...
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is ... incidence of depression worldwide is anticipated to drive the market growth in the ... demand for antidepressants in the recent years. Continue ... ... ...
(Date:1/23/2017)... SAN DIEGO , 23. Januar 2017  ResMed ... China ) und 3B Medical ( Winter ... sich auf eine Vereinbarung über die Beilegung aller globalen ... ist der Verkauf ihrer bestehenden Produkte im ... eine einmalige Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology: